Skip to content

Evaluation of Efficacy and Safety of Intradiscal Gelified Ethanol in Refractory Cervical Discogenic Pain

Intradiscal Gelified Ethanol in Refractory Cervical Discogenic Pain : a Interventional, Prospective, Multi-center, Open-label Study.

Status
Not yet recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05969392
Acronym
DISCOCERV
Enrollment
60
Registered
2023-08-01
Start date
2025-04-30
Completion date
2026-04-30
Last updated
2025-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Discogenic Pain, Pain, Cervical

Brief summary

The purpose of this study is to assesse safety and efficacy of the Intradiscal Gelified Ethanol for treatment in refractory cervical discogenic pain.

Detailed description

After being informed about the study and potential tisks, all patients giving written informed consent will undergo a inclusion visit (CT scan and X ray at least) for study entry. At Day 0, operation with Intradiscal Gelified Ethanol will be performed by the investigator. Follow visit will be performed at 3 months and 12 months

Interventions

DEVICEIntradiscal Gelified Ethanol (Discogel)

Intradiscal percutaneous injection of an intradiscal Gelified Ethanol

Sponsors

Gelscom SAS
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No

Inclusion criteria

* Patient 18 years or older; * Pain refractory to conservative treatments for more than 2 months, non-surgical patients * Cervicobrachialgia due to disc herniation * Chronic discogenic pain (1 or 2 cervical discs) with concordant MRI; * Patient agreeing to participate in the study and having given written consent; * Patient enrolled in a health insurance plan.

Exclusion criteria

* Prior surgical treatment of the disc(s) studied; * Sick leave of more than 12 months secondary to painful symptoms; * Patient with Modic 1 score or more * History of cognitive-behavioral disorders that could affect the completion of self-questionnaires; * Local or systemic infection, or suspicion of infection; * Severe coagulation disorders; * Other inflammatory rheumatic disease; * Severe underlying pathology with life expectancy \<1 year; * Women of childbearing age who are pregnant at the inclusion visit or who wish to become pregnant before the administration of the treatment (V0); * Known allergy to contrast material and/or local anesthetic substances; * Patients who cannot read or write Italian; * Major person benefiting from a legal protection regime (guardianship, curatorship, safeguard of justice);

Design outcomes

Primary

MeasureTime frameDescription
the mean change in pain intensity assessed by a verbal local rating scale (pain intensity numerical scale) between the pre-treatment measurement (inclusion visi) and the post-treatment measurement (Visit 2 at the 3 months)3 monthsIn a 11-point numeric scale, 0 represents NO PAIN and 10 represents EXTREME PAIN (e.g., pain as bad as you can imagine and worst pain imaginable).

Secondary

MeasureTime frameDescription
Change in pain cervical intensity using the verbal local rating scale [12 monthsScores range from 0-10. In a 11-point numeric scale, 0 represents NO PAIN and 10 represents EXTREME PAIN (e.g., pain as bad as you can imagine and worst pain imaginable).
Change of consumption of painkillers12 monthsNumber, frequency and dosage of pain relief treatments will be combine todescribe the difference in painkiller consumption before and after the operation
Incidence of complication and adverse event rates12 monthsIncidence of adverse event during 12 months after the treatment
Change in ability to manage everyday-life activity (Neck Disability Index (NDI) scale) [Time Frame : inclusion, 3 and 12 months after treatment].12 monthsThe Neck Disability Index (NDI) is used to measure pain-related disability associated with activities of daily living in people with neck pain (index between 0 and 50). The original report provided scoring intervals for interpretation, as follows: 0 - 4 = no disability, 5 - 14 = mild, 15 - 24 = moderate, 25 - 34 = severe, above 34 = complete. The NDI contains 10 items-7 related to activities of daily living, 2 related to pain, and 1 related to concentration.
Subjective evaluation MacNab12 months after treatmentThe MacNab's scale is layered into 4 levels (excellent, good, fair and poor) according to the patient's well-being after surgery or procedure.The scores were divided into the following four grades: 75-100% (excellent), 50-74% (good), 25-49% (fair) and 0-24% (poor). Excellent is defined as No pain; no restriction of activity. Good is defined as Occasional pain of sufficient severity to interfere with the patient's ability to do his normal work or his capacity to enjoy himself in leisure hours.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026